Brief: Ascletis Pharma Says IND Application Of Asc10 Oral Inhibitor Drug Targeting Rna-Dependent Rna Polymerase For Covid-19, Accepted By NMPA
04/08/2022 02:24
Aug 4 (Reuters) - Ascletis Pharma Inc 1672.HK :
* IND APPLICATION OF ASC10 ORAL INHIBITOR DRUG TARGETING
RNA-DEPENDENT RNA POLYMERASE FOR COVID-19, ACCEPTED BY NMPA
Source text for Eikon: ID:
Further company coverage: 1672.HK
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management